These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26804020)

  • 21. Immune and inflammatory role in renal disease.
    Imig JD; Ryan MJ
    Compr Physiol; 2013 Apr; 3(2):957-76. PubMed ID: 23720336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptors: emerging concepts in kidney disease.
    Anders HJ; Schlöndorff D
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):177-83. PubMed ID: 17420659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New perspective for drug discovery and clinical development in kidney disease].
    Miyata T; Kikuchi K; Saito K
    Nihon Jinzo Gakkai Shi; 2012; 54(5):610-4. PubMed ID: 22991841
    [No Abstract]   [Full Text] [Related]  

  • 24. Human clinical trials in lupus nephritis.
    Dooley MA; Falk RJ
    Semin Nephrol; 2007 Jan; 27(1):115-27. PubMed ID: 17336693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
    Lourenço EV; Wong M; Hahn BH; Palma-Diaz MF; Skaggs BJ
    Arthritis Rheumatol; 2014 Mar; 66(3):674-85. PubMed ID: 24574228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic kidney disease.
    Bock GH; Vernier RL
    Am Fam Physician; 1980 Nov; 22(5):87-96. PubMed ID: 6448541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the management of microscopic polyangiitis: past, present and future.
    Jayne D
    Curr Opin Rheumatol; 2008 Jan; 20(1):3-9. PubMed ID: 18281850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue factor in crescentic glomerulonephritis.
    McCluskey RT
    Am J Pathol; 1997 Mar; 150(3):787-92. PubMed ID: 9060816
    [No Abstract]   [Full Text] [Related]  

  • 29. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: an introduction].
    Feriozzi S
    G Ital Nefrol; 2012; 29(3):267-73; discussion 292. PubMed ID: 22718449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunostimulant therapy of kidney diseases].
    Karastanev I
    Vutr Boles; 1982; 21(3):8-13. PubMed ID: 6180558
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug discovery in renal disease--towards a more efficient framework.
    Miyata T; Ando T; Hiragi H; Watanabe K; Yamamoto F; Vaughan DE; Kurokawa T; Oshima Y; van Ypersele de Strihou C; Takeuchi M
    Nat Rev Nephrol; 2014 May; 10(5):290-6. PubMed ID: 24642801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune aspects of renal diseases.
    Wilson CB
    JAMA; 1987 Nov; 258(20):2957-61. PubMed ID: 2959799
    [No Abstract]   [Full Text] [Related]  

  • 33. Rituximab treatment in lupus nephritis--where do we stand?
    Gunnarsson I; Jonsdottir T
    Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lupus nephritis: where are we now?
    Lightstone L
    Curr Opin Rheumatol; 2010 May; 22(3):252-6. PubMed ID: 20305561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine and Human Lupus Nephritis: Pathogenic Mechanisms and Theoretical Strategies for Therapy.
    Pedersen HL; Horvei KD; Thiyagarajan D; Seredkina N; Rekvig OP
    Semin Nephrol; 2015 Sep; 35(5):427-38. PubMed ID: 26573545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intravenous immunoglobulins in the treatment of glomerulopathies].
    Floccari F; Palla R; Polito P; Campo S; Aloisi C; Buemi M
    G Ital Nefrol; 2007; 24(4):311-9. PubMed ID: 17659502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of autoimmune (lupus-like) glomerulonephritis in murine models.
    Hicks J; Bullard DC
    Ultrastruct Pathol; 2006; 30(5):345-59. PubMed ID: 17090514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases.
    Van Herle K; Behne JM; Van Herle A; Blaschke TF; Smith TJ; Yeaman MR
    Annu Rev Pharmacol Toxicol; 2012; 52():523-47. PubMed ID: 22235861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of macrophage migration inhibition factor in kidney disease.
    Lan HY
    Nephron Exp Nephrol; 2008; 109(3):e79-83. PubMed ID: 18663334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.